MUMBAI (Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd's shares opened down 6.4 percent on Monday, after the U.S. Food and Drug Administration issued the firm a warning letter on its key Halol manufacturing plant in western India.
The stock has fallen more than 10 percent since the beginning of the year.
The FDA's warning to Sun Pharma was based on an inspection of the Halol plant the agency conducted in Sept. 2014, after which it outlined a series of concerns it observed with the manufacturing processes there.
Sun Pharma said on Saturday that it had been working on resolving the concerns, and is assessing what more it needs to now do.
(Reporting by Zeba Siddiqui in Mumbai; Editing by Clara Ferreira Marques)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app